OptimizeRx Corp

OptimizeRx Corp(OPRX)股票分析

$7.950

+0.122 (+1.53%)收盘时

Loading chart…
High
8.090
Open
7.830
VWAP
7.88
Vol
271.58K
Mkt Cap
188.54M
Low
7.600
Amount
2.14M
EV/EBITDA, TTM
37.95

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

AI analysis of OptimizeRx Corp (OPRX)

buy

OptimizeRx Corp (OPRX) appears to be a good buy right now, trading at $7.95 with a forward P/E of 7.97, indicating it may be undervalued compared to its earnings potential. Additionally, the company has shown a significant gross margin improvement, reaching 71.32% in Q2 2026, which supports profitability despite recent revenue challenges. The main risk is the revenue decline of 30% year-over-year reported in Q2 2026, which could impact future performance.

Analyst Ratings (1)

+206.04% upside
Buy
1 Buy
0 Hold
0 Sell
Current: 7.95
最低
17.00
平均
24.33
最高
32.00

Stifel

2026-08-13

目标价

$12

Buy

B. Riley

2026-05-13

目标价

$10

Buy

Lake Street

2026-05-13

目标价

$11

Buy

Stifel

2026-05-13

目标价

$14

Buy

Stifel

2026-03-06

目标价

$17

Buy

估值指标

The current forward P/E ratio for OptimizeRx Corp (OPRX) is 7.97, compared to its 5-year average forward P/E of 48.39.

Forward P/E

Undervalued
5Y Average P/E
48.39
Current P/E
7.97
高估
84.97
低估
11.81

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
43.67
Current EV/EBITDA
37.95
高估
90.13
低估
-2.79

Forward P/S

Fair
5Y Average P/S
4.27
Current P/S
1.39
高估
8.96
低估
-0.43

Alphio AI Price Scenarios for OPRX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OPRX

$17.89

情景价格

B

Base

Base · 50%OPRX

$16.60

情景价格

B

Bear

Bear · 25%OPRX

$15.41

情景价格

Whales holding OPRX

R

Rice Hall James & Associates, LLC

+ HoldingOPRX

+7.27%

3M Return

事件时间线

2026-08-12 (ET)

17:00:00

OptimizeRx Appoints Andy D'Silva as CFO

16:31:00

OptimizeRx Q2 Revenue at $20.5M, Exceeds Expectations

16:30:00

Company Reiterates FY 2026 Guidance, Expects Revenue of $95M to $100M

2026-07-23 (ET)

08:00:00

OptimizeRx Appoints Sarah Bast as Chief Marketing Officer

2026-05-12 (ET)

16:10:00

Company Confirms FY26 Adjusted EBITDA Outlook of $21M to $25M

资讯

OPRX FAQ — answered by Alphio AI

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

OptimizeRx Corp (OPRX) appears to be a good buy right now, trading at $7.95 with a forward P/E of 7.97, indicating it may be undervalued compared to its earnings potential. Additionally, the company has shown a significant gross margin improvement, reaching 71.32% in Q2 2026, which supports profitability despite recent revenue challenges. The main risk is the revenue decline of 30% year-over-year reported in Q2 2026, which could impact future performance.

1 analysts cover OPRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始